Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects.

Trial Profile

A Phase 1, randomized, placebo-controlled, ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HL161BKN following single intravenous and subcutaneous doses in healthy subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs HL 161 (Primary) ; HL 161 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Jan 2019 According to a Roivant Sciences media release, updated data form this study will be presented at the J.P. Morgan Healthcare Conference.
    • 10 Jul 2018 According to a Roivant Sciences media release, preliminary clinical data from this study will be presented today at the First Annual Pipeline Day of the Company.
    • 13 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top